The US National Institutes of Health (NIH) is to build on its ground-breaking ACTT trial of Gilead Sciences Inc.’s remdesivir in COVID-19 patients by adding Eli Lilly & Co.’s rheumatoid arthritis drug Olumiant (baricitinib) into the mix for patients with more severe disease.
The initial ACTT data formed the basis of the US Food and Drug Administration’s emergency use approval of remdesivir on...







